PlumX Metrics
Embed PlumX Metrics

Vaccines for the prevention of human papillomavirus and associated gynecologic diseases: A review

Obstetrical and Gynecological Survey, ISSN: 0029-7828, Vol: 61, Issue: 6 SUPPL. 1, Page: S26-31
2006
  • 24
    Citations
  • 0
    Usage
  • 40
    Captures
  • 0
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Review Description

Routine vaccination programs have had a substantial impact on reducing the prevalence of a variety of infectious diseases. In light of the fact that human papillomavirus (HPV) is a prerequisite for virtually every case of cervical cancer and genital warts occurring worldwide, vaccination may be the most effective mechanism to prevent HPV infection and HPV-associated disease. HPV vaccines are created from noninfectious virus-like particles (VLPs) of the major capsid protein, L1, that closely mimic natural HPV virions. Proof-of-principle trials of monovalent vaccines that protect against high-risk HPV types such as HPV 16 or 18 have confirmed that intramuscular injection with VLPs induces the production of HPV type-specific neutralizing antibodies. A bivalent vaccine incorporating oncogenic HPV types 16 and 18 was shown to be safe, well tolerated, and 100% efficacious in preventing persistent HPV infection. A quadrivalent vaccine that protects against genital wart-causing HPV types (HPV 6 and 11) and oncogenic HPV types (HPV 16 and 18) demonstrated 100% efficacy in preventing clinical disease. Because VLP vaccines are prophylactic, vaccination before exposure to HPV will result in the greatest public health benefit; therefore, a successful vaccination program should target preadolescents and stress the importance of vaccination before sexual debut. Copyright © 2006 by Lippincott Williams & Wilkins.

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know